Isofol made several important announcements this morning. The company reports that more than 200 of the planned 440 patients have been randomised in the ongoing phase III trial AGENT. Further, Isofol reports that the phase I/IIa study CC-005 now has been completed and that the gene expression method has been validated by a commercial laboratory.